Breaking News Instant updates and real-time market news.

SLDB

Solid Biosciences

$8.86

-0.3397 (-3.69%)

, SRPT

Sarepta

$112.12

-9.97 (-8.17%)

07:03
05/14/19
05/14
07:03
05/14/19
07:03

Solid Biosciences downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs analyst Salveen Richter downgraded Solid Biosciences (SLDB) to Sell from Neutral after the company disclosed additional safety events with the first patient treated at the new high dose in the Phase 1/2 micro-dystrophin gene therapy study in Duchenne muscular dystrophy. Richter, who noted that he has previously expressed concern regarding a higher SGT-001 dose given safety events at the low dose, sees continued risk with the SGT-001 program as the trial continues to enroll, he tells investors. The analyst, who views SGT-001 as "suboptimal" versus competitor Sarepta's (SRPT) gene therapy, cut his price target on Solid shares to $4 from $5.

SLDB

Solid Biosciences

$8.86

-0.3397 (-3.69%)

SRPT

Sarepta

$112.12

-9.97 (-8.17%)

  • 06

    Jun

  • 13

    Jun

  • 19

    Aug

SLDB Solid Biosciences
$8.86

-0.3397 (-3.69%)

02/08/19
SBSH
02/08/19
UPGRADE
Target $8
SBSH
Neutral
Citi upgrades Solid Biosciences to Neutral after Sell thesis played out
Citi analyst Joel Beatty upgraded Solid Biosciences to Neutral from Sell while lowering his price target for the shares to $8 from $31. The analyst says that with the initial clinical data for SGT-001 announced yesterday, his Sell thesis has played out. He moves to a Neutral rating because he believes that the next dosing cohort is "unlikely to generate strong enough data to support a commercially competitive profile."
02/08/19
GSCO
02/08/19
NO CHANGE
Target $21
GSCO
Buy
Goldman says Orchard track record stands out amid disappointments in gene space
Goldman Sachs analyst Graig Suvannavejh noted that February 7 was "a day of disappointment" in the gene therapy and gene editing space, as Solid Biosciences (SLDB) and Sangamo (SGMO) both reported clinical efficacy data that missed investor expectations and "perhaps also raised concerns about the long-term promise of gene-based approaches." Within this context, he pointed out that he believes Orchard Therapeutics (ORTX) has "the most robust clinical experience in gene therapy, with over 150 patients treated across multiple product candidates and indications." The analyst, who expects new clinical data for Orchard candidates OTL-101 and OTL-102 to be presented later this month to re-affirm his confidence, reiterated his Buy rating and $21 price target on Orchard shares.
02/25/19
FBCO
02/25/19
NO CHANGE
Target $47
FBCO
Neutral
Roche may spark another bull run for gene therapy names, says Credit Suisse
Credit Suisse analyst Martin Auster notes that the Wall Street Journal recently reported that Roche (RHHBY) is nearing a deal with Spark Therapeutics (ONCE) for $5B. The analyst believes the transaction value implies the re-emergence of Spark's hemophilia A gene therapy program with a competitive profile and substantial value assigned to additional pipeline programs, such as SPK-3006 for Pompe, and the technology platform. Spark's acquisition would further strengthen the company's position in the hemophilia space, he contends. Further, Auster argues that the deal may increase M&A interest among other gene therapy names in his coverage universe, which include BioMarin (BMRN), Sarepta (SRPT), Ultragenyx (RARE), PTC (PTC) and Solid Biosciences (SLDB). He sees particularly strong read-through to Sarepta. The analyst reiterates a Neutral rating and a $47 price target on Spark's shares.
05/14/19
FBCO
05/14/19
DOWNGRADE
FBCO
Underperform
Solid Biosciences downgraded to Underperform from Neutral at Credit Suisse
SRPT Sarepta
$112.12

-9.97 (-8.17%)

04/11/19
EVER
04/11/19
INITIATION
Target $175
EVER
Outperform
Sarepta initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Sarepta with an Outperform rating and a price targets of $175. The analyst cites the company's opportunity in Duchenne muscular dystrophy and dominant position in its domain.
04/17/19
BTIG
04/17/19
NO CHANGE
Target $190
BTIG
Buy
Sarepta remains in leading position on DMD and LGMD, says BTIG
BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta after attending the MDA Clinical & Scientific Conference this week, saying that its AAVrh74 gene therapies have received "a lot of attention" in the areas of Duchenne Muscular Dystrophy, or DMD, and Limb Girdle Muscular Dystrophy, or LGMD. The analyst also notes that many of the sessions discussing novel potential gene therapies for DMD/LGMD have been "packed with physicians / scientists / industry reps", adding that manufacturing scale up for gene therapies has also been widely discussed.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $208
PIPR
Overweight
Sarepta continues to make progress in gene therapy, says Piper Jaffray
Sarepta Therapeutics continues to make progress on all fronts with their gene therapy platform, Piper Jaffray analyst Danielle Brill tells investors in a research note following the company's Q1 results. Sarepta has now dosed 18 patients in their ongoing microdystrophin gene therapy trial, and remain on track to complete dosing in Q2, says the analyst. She reiterates an Overweight rating on the shares with a $208 price target.
05/09/19
BARD
05/09/19
NO CHANGE
BARD
Outperform
Baird names Sarepta a 'Fresh Pick' ahead of Pfizer data
Baird analyst Brian Skorney named Sarepta as a "Fresh Pick" ahead of the report of competitive data due in late June from Pfizer's (PFE) Duchenne muscular dystrophy program that he predicts will "fall flat." If that turns out to be the case, it should remove the most significant overhang on Sarepta shares, contends Skorney, who keeps an Outperform rating on Sarepta.

TODAY'S FREE FLY STORIES

CVNA

Carvana

$66.99

-0.175 (-0.26%)

21:14
05/21/19
05/21
21:14
05/21/19
21:14
Syndicate
Carvana 4.2M share Secondary priced at $65.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 18

    Jun

  • 22

    May

INSM

Insmed

$26.37

-1.71 (-6.09%)

20:57
05/21/19
05/21
20:57
05/21/19
20:57
Syndicate
Insmed 9.62M share Secondary priced at $26.00 »

Morgan Stanley, SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 22

    May

LOW

Lowe's

$111.10

1.86 (1.70%)

, ADI

Analog Devices

$99.98

2.54 (2.61%)

20:25
05/21/19
05/21
20:25
05/21/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$111.10

1.86 (1.70%)

ADI

Analog Devices

$99.98

2.54 (2.61%)

TGT

Target

$72.05

-0.05 (-0.07%)

VFC

VF Corp.

$92.13

1.43 (1.58%)

AAP

Advance Auto Parts

$161.08

2.42 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 12

    Jun

  • 18

    Jun

20:25
05/21/19
05/21
20:25
05/21/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

SPY

SPDR S&P 500 ETF Trust

$286.50

2.55 (0.90%)

, SPX

S&P 500

$0.00

(0.00%)

20:24
05/21/19
05/21
20:24
05/21/19
20:24
Periodicals
China ambassador to U.S. says Beijing ready to continue talks, Reuters reports »

China ambassador to the…

SPY

SPDR S&P 500 ETF Trust

$286.50

2.55 (0.90%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEO

NeoGenomics

$21.81

-1.38 (-5.95%)

20:12
05/21/19
05/21
20:12
05/21/19
20:12
Syndicate
NeoGenomics 7M share Secondary priced at $21.25 »

Morgan Stanley, SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

  • 06

    Jun

  • 13

    Nov

  • 23

    May

BAM

Brookfield

$47.03

0.02 (0.04%)

, BX

Blackstone

$41.79

1.17 (2.88%)

19:29
05/21/19
05/21
19:29
05/21/19
19:29
Periodicals
Brookfield, Fortress among bidders for Anbang hotel portfolio, Bloomberg says »

Brookfield Asset…

BAM

Brookfield

$47.03

0.02 (0.04%)

BX

Blackstone

$41.79

1.17 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 08

    Aug

GOLD

Barrick Gold

$12.12

-0.07 (-0.57%)

19:18
05/21/19
05/21
19:18
05/21/19
19:18
Hot Stocks
Barrick says Acacia proposal reflects 'fair value' following Tanzania talks »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

$25.38

-0.42 (-1.63%)

19:04
05/21/19
05/21
19:04
05/21/19
19:04
Hot Stocks
Sea Limited reports Q1 QAUs up 114.4% from last year »

Reports Q1 Quarterly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SE

Sea Limited

$25.38

-0.42 (-1.63%)

19:02
05/21/19
05/21
19:02
05/21/19
19:02
Earnings
Sea Limited reports Q1 EPS (64c), consensus (68c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SNE

Sony

$51.01

-1.195 (-2.29%)

18:48
05/21/19
05/21
18:48
05/21/19
18:48
Periodicals
Sony aims to bolster cash flow to better compete in chips, games, NAR says »

Sony is seeking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jun

OOMA

Ooma

$14.49

-0.45 (-3.01%)

, CVI

CVR Energy

$47.29

0.9 (1.94%)

18:47
05/21/19
05/21
18:47
05/21/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ooma…

OOMA

Ooma

$14.49

-0.45 (-3.01%)

CVI

CVR Energy

$47.29

0.9 (1.94%)

PVH

PVH Corp.

$108.53

2.5075 (2.37%)

PSTG

Pure Storage

$20.60

0.6 (3.00%)

JWN

Nordstrom

$37.88

0.42 (1.12%)

URBN

Urban Outfitters

$27.01

0.05 (0.19%)

TOL

Toll Brothers

$38.34

0.82 (2.19%)

ONCS

OncoSec

$3.95

0.149 (3.92%)

EKSO

Ekso Bionics

$1.84

-0.06 (-3.16%)

TOCA

Tocagen

$8.81

-0.18 (-2.00%)

LIQT

LiqTech

$9.29

-0.21 (-2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 10

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 09

    Jul

  • 22

    May

  • 22

    May

  • 22

    May

TREX

Trex Company

$61.44

2.38 (4.03%)

18:45
05/21/19
05/21
18:45
05/21/19
18:45
Hot Stocks
Trex Company CEO: There is no demand issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CRMT

America's Car-Mart

$101.76

1.74 (1.74%)

18:34
05/21/19
05/21
18:34
05/21/19
18:34
Earnings
America's Car-Mart reports Q4 EPS $2.07, consensus $1.82 »

Reports Q4 revenue $177M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 30

    May

  • 13

    Nov

JCOM

j2 Global

$87.23

0.75 (0.87%)

18:25
05/21/19
05/21
18:25
05/21/19
18:25
Hot Stocks
j2 Global CFO sells 5.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 05

    Jun

NVS

Novartis

$82.38

0.36 (0.44%)

18:24
05/21/19
05/21
18:24
05/21/19
18:24
Hot Stocks
Novartis CEO: We are entering an exciting growth phase for the company »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

EADSY

Airbus

$0.00

(0.00%)

18:20
05/21/19
05/21
18:20
05/21/19
18:20
Periodicals
Airbus in talks to find resolution to German arms export row, Reuters says »

Airbus CEO Guillaume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGRO

Adecogro

$6.50

0.07 (1.09%)

18:19
05/21/19
05/21
18:19
05/21/19
18:19
Earnings
Adecogro reports Q1 adjusted EBITDA $58.3M, down 5.9% from last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,149.14

10.81 (0.95%)

, GOOGL

Alphabet Class A

$1,154.26

8.98 (0.78%)

18:01
05/21/19
05/21
18:01
05/21/19
18:01
Hot Stocks
Google updates policy on abortion-related ads »

Google said in a post…

GOOG

Alphabet

$1,149.14

10.81 (0.95%)

GOOGL

Alphabet Class A

$1,154.26

8.98 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 27

    Oct

HAIN

Hain Celestial

$23.90

0.45 (1.92%)

17:50
05/21/19
05/21
17:50
05/21/19
17:50
Hot Stocks
Engaged Capital raises stake in Hain Celestial to 20.2% from 18.3% »

Engaged Capital raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

17:48
05/21/19
05/21
17:48
05/21/19
17:48
Hot Stocks
Nintendo to end 'Animal Crossing,' 'Fire Emblem' mobile game service in Belgium »

Nintendo announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

  • 11

    Jun

URBN

Urban Outfitters

$27.01

0.05 (0.19%)

17:44
05/21/19
05/21
17:44
05/21/19
17:44
Hot Stocks
Urban Outfitters sees Q2 URBN retail SSS in low single-digit negative range »

Says guidance based on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 04

    Jun

GLD

SPDR Gold Shares

$120.34

-0.31 (-0.26%)

17:42
05/21/19
05/21
17:42
05/21/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 739.69MT from 736.17MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASCMA

Ascent Capital

$0.91

0.0502 (5.87%)

17:38
05/21/19
05/21
17:38
05/21/19
17:38
Hot Stocks
Ascent Capital and Monitronics International announce restructuring support pact »

Ascent Capital Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRS

TriMas

$30.33

0.39 (1.30%)

17:33
05/21/19
05/21
17:33
05/21/19
17:33
Hot Stocks
TriMas VP Joshua Sherbin sells over $646K in company shares »

TriMas VP Joshua Sherbin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.